Targeted delivery in primary and metastatic brain tumors: Summary report of the seventh annual meeting of the blood-brain barrier disruption consortium

Nancy D. Doolittle, Lauren E. Abrey, Nicolay Ferrari, Walter A. Hall, Edward R. Laws, Roger E. McLendon, Leslie L. Muldoon, David Peereboom, Darryl R. Peterson, C. Patrick Reynolds, Peter Senter, Edward A. Neuwelt

Research output: Contribution to journalArticle

19 Scopus citations

Abstract

The November 2000 NIH report of the Brain Tumor Progress Review Group identified delivering and targeting therapeutic agents as a priority in the treatment of malignant brain tumors. For this reason, the seventh annual Blood-Brain Barrier Disruption Consortium meeting, partially funded by an NIH R13 Grant, focused on recent advances in targeted delivery to the central nervous system, clinical trials for primary and metastatic brain tumors using enhanced chemotherapy delivery, and strategies to lessen the toxicities associated with dose intensive treatments, using thiols.

Original languageEnglish (US)
Pages (from-to)1702-1709
Number of pages8
JournalClinical Cancer Research
Volume8
Issue number6
StatePublished - Jan 1 2002

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Targeted delivery in primary and metastatic brain tumors: Summary report of the seventh annual meeting of the blood-brain barrier disruption consortium'. Together they form a unique fingerprint.

  • Cite this

    Doolittle, N. D., Abrey, L. E., Ferrari, N., Hall, W. A., Laws, E. R., McLendon, R. E., Muldoon, L. L., Peereboom, D., Peterson, D. R., Reynolds, C. P., Senter, P., & Neuwelt, E. A. (2002). Targeted delivery in primary and metastatic brain tumors: Summary report of the seventh annual meeting of the blood-brain barrier disruption consortium. Clinical Cancer Research, 8(6), 1702-1709.